Ophthalmology Times - Ophthalmology news, articles, and events
Panelists discuss how successful implementation of the port delivery system requires careful attention to surgical technique during both initial implantation and subsequent refill procedures, with specialized training and protocols that differ significantly from standard intravitreal injections in terms of procedural steps, sterility requirements, and patient preparation.
FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry …
2024年11月19日 · The FDA has accepted the resubmitted new drug application (NDA) from Aldeyra Therapeutics for its first-in-class investigational candidate, topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease.At the same time, Aldeyra is choosing to expand their option agreement with AbbVie, granting the manufacturer more cash to bring the drug to market. 1
What your patients need to know about eye color-changing drops
2024年8月28日 · The American Academy of Ophthalmology indicates that consumers who may see the eye color-changing drops advertised and used on TikTok or elsewhere online should be advised that they are not FDA approved.
AAO 2024: Livionex reports positive end-of-phase 2 meeting with …
2024年10月18日 · According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.
Ophthalmology Times 2024 wrap-up: A year of innovation and …
2024年12月26日 · As 2024 comes to a close, we here at Ophthalmology Times and the greater Eye Care Network would like to thank you–the reader. Throughout the year, we have had the privilege of covering a wide range of topics in ophthalmology. As always, stay tuned to see highlights from the year from all other Eye Care Brands on Ophthalmology Times.Now, we take a look back at some of the highlights of 2024 ...
Johnson & Johnson launches TECNIS Odyssey IOL in US
2024年10月1日 · Johnson & Johnson is expanding the launch of its presbyopia-correcting intraocular lense (IOL), TECNIS Odyssey, in the US.. The TECNIS Odyssey IOL is a new full vision range IOL, built on the TECNIS platform from Johnson & Johnson, which according to the company provides two times better contrast in low lighting than PanOptix. 1 Peter Menziuso, company group chairman, Vision, Johnson & Johnson ...
New canalicular gel shows promise for dry eye treatment
2024年11月13日 · Reviewed by Mark Packer, MD; and Eric Donnenfeld, MD. In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has shown it to be a safe, well-tolerated, and effective treatment for dry eye. 1 This device offers a new option for managing a condition that affects millions of patients.. A study, led by first author Mark Packer, MD ...
FDA approves Bausch + Lomb’s enVista Envy range of IOLs
2024年10月14日 · Key Takeaways. enVista Envy IOLs provide a continuous range of vision with high dysphotopsia tolerance, enhancing cataract surgery outcomes. U.S. and Canadian trials showed high patient satisfaction, with minimal issues related to glare and close object viewing.
Study suggests potential link between semaglutide and risk of non ...
2024年7月9日 · Boston researchers led by first author Jimena Tatiana Hathaway, MD, MPH, reported that there is a potential risk of the development of non-arteritic ischemic optic neuropathy (NAION) 1 associated with prescriptions for semaglutide (Wegovy, Ozempic, Novo Nordisk). Prescriptions with semaglutide are FDA approved to treat obesity and type 2 …
Specular microscopy: A practical guide for the assessment of …
2024年12月17日 · Specular microscopy is essential for evaluating corneal endothelial health, especially pre-surgery, emphasizing device-specific data accuracy and repeatability. Nidek CEM-530 and Tomey EM-4000 were assessed for ECD and CCT, showing excellent intradevice repeatability but notable interdevice ...